Relationship between serum NMDA receptor antibodies and response to antipsychotic treatment in first-episode psychosis

Pollak, Thomas A, Vincent, Anegla, Iyegbe, Conrad, Coutinho, Ester, Jacobson, Leslie, Rujescu, Dan, Stone, James, Jezequel, Julie, Rogemond, Veronique, Jamain, Stephane, Groc, Laurent, David, Anthony, Egerton, Alice, Kahn, Rene S, Honnorat, Jerome et al. (2021) Relationship between serum NMDA receptor antibodies and response to antipsychotic treatment in first-episode psychosis. Biological Psychiatry, 90 (1). pp. 9-15. ISSN 0006-3223

This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/108256/

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher’s version. Please see the URL above for details on accessing the published version.

Copyright and reuse:
Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.
Relationship Between Serum NMDA Receptor Antibodies and Response to Antipsychotic Treatment in First-Episode Psychosis

Thomas A. Pollak, Angela Vincent, Conrad Iyegbe, Ester Coutinho, Leslie Jacobson, Dan Rujescu, James Stone, Julie Jezequel, Veronique Rogemond, Stephane Jamain, Laurent Groc, Anthony David, Alice Egerton, Rene S. Kahn, Jerome Honnorat, Paola Dazzan, Marion Leboyer, and Philip McGuire

ABSTRACT
BACKGROUND: When psychosis develops in NMDA receptor (NMDAR) antibody encephalitis, it usually has an acute or subacute onset, and antipsychotic treatment may be ineffective and associated with adverse effects. Serum NMDAR antibodies have been reported in a minority of patients with first-episode psychosis (FEP), but their role in psychosis onset and response to antipsychotic treatment is unclear.

METHODS: Sera from 387 patients with FEP (duration of psychosis <2 years, minimally or never treated with anti-psychotics) undergoing initial treatment with amisulpride as part of the OPTiMiSE (Optimization of Treatment and Management of Schizophrenia in Europe) trial (ClinicalTrials.gov number NCT01248195) were tested for NMDAR IgG antibodies using a live cell–based assay. Symptom severity was assessed using the Positive and Negative Syndrome Scale and the Clinical Global Impressions Scale at baseline and again after 4 weeks of treatment with amisulpride.

RESULTS: At baseline, 15 patients were seropositive for NMDAR antibodies and 372 were seronegative. The seropositive patients had similar symptom profiles and demographic features to seronegative patients but a shorter duration of psychosis (median 1.5 vs. 4.0 months; p = .031). Eleven seropositive and 284 seronegative patients completed 4 weeks of amisulpride treatment: after treatment, there was no between-groups difference in improvement in Positive and Negative Syndrome Scale scores or in the frequency of adverse medication effects.

CONCLUSIONS: These data suggest that in FEP, NMDAR antibody seropositivity alone is not an indication for using immunotherapy instead of antipsychotic medications. Further studies are required to establish what proportion of patients with FEP who are NMDAR antibody seropositive have coexisting cerebrospinal fluid inflammatory changes or other paraclinical evidence suggestive of a likely benefit from immunotherapy.

https://doi.org/10.1016/j.biopsych.2020.11.014

Serum NMDA receptor (NMDAR) antibodies have been inconsistently detected in a subgroup of patients with psychosis, with the proportion varying (between 0% and 20%) with the type of assay used and the nature of the patient sample (1–4). The clinical significance of NMDAR antibodies in patients with psychotic disorders remains unclear. It has been suggested that they may demarcate an autoimmune encephalitis caught early or a forme fruste of autoimmune encephalitis that has been misdiagnosed as a primary psychotic disorder. However, NMDAR antibodies are also detectable in healthy individuals, with some studies reporting similar rates to those observed in patient populations (5).

If, in a subset of patients, psychosis is caused by NMDAR antibodies, treatment with antipsychotic medication might not be effective. Case reports and series of patients with NMDAR antibody encephalitis have described a poor response to antipsychotic treatment in the initial, psychiatric phase of the disease. In addition, patients with NMDAR antibody encephalitis may be particularly sensitive to the adverse effects of antipsychotic medication, such as pronounced rigidity, rhabdomyolysis, and neuroleptic malignant syndrome (6,7). However, the effectiveness and safety of antipsychotic medication has yet to be examined in patients who have NMDAR antibodies and present with psychosis in the absence of encephalitis.

Typically, NMDAR antibody encephalitis has a subacute onset, defined as a rapid progression of symptoms of less than 3 months in duration (8). If NMDAR antibodies underlie the onset of some cases of psychosis, one might therefore expect a similarly rapid progression and, thus, shorter duration of untreated psychosis before presentation to clinical services. This hypothesis remains to be tested.

It has been suggested that immunotherapy may be indicated as an alternative to antipsychotic medication in patients with psychosis who are seropositive for NMDAR antibodies (9) (and anecdotally, we have heard of such patients being offered...
immunotherapy). This is partly due to observations that in the context of NMDAR antibody encephalitis, antipsychotic medications may lack efficacy in reducing psychotic symptoms, whereas immunotherapy may be effective (9,10). However, these observations remain controversial (11,12). Evaluating the safety and efficacy of antipsychotic medication in NMDAR antibody seropositive or seronegative patients with psychosis may help to resolve this issue.

The main aims of this study were to examine the relationship between serum NMDAR antibodies and 1) symptom profile at presentation and 2) response to antipsychotic treatment in a large cohort of patients with first-episode psychosis (FEP). We tested the hypothesis that, compared with seronegative patients, seropositive patients would have 1) a shorter duration of psychosis and 2) a poor therapeutic response but a greater frequency of adverse effects.

METHODS AND MATERIALS

Subjects

We studied patients in OPTiMiSE (Optimization of Treatment and Management of Schizophrenia in Europe; www.optimisetal.eu), a European Union–funded study of the management of FEP that recruited patients between May 26, 2011, and May 15, 2016. Full details of the trial have been reported elsewhere (13). Briefly, inclusion required that patients had a diagnosis of first-episode schizophrenia, schizoaffective disorder, or schizoaffective psychosis and were either naïve to antipsychotic medication or had received no more than 2 weeks of medication in the previous year or no more than 6 weeks in their lifetime. Inclusion also required that the time between psychosis onset and study entry was less than 2 years. Patients were excluded if there was any suspicion of an organic etiology; they had a known intolerance to one of the study drugs; they met any of the contraindications for any of the study drugs as mentioned in the (local) package insert texts; they were coercedly treated or represented by a legal guardian, or both, or under legal custody; or they were pregnant or breastfeeding. Recruitment involved centers in the United Kingdom, the Netherlands, Denmark, France, Austria, Czech Republic, Germany, Israel, Italy, Poland, Spain, Australia, Bulgaria, and Romania (Table S1).

This study was restricted to patients in whom serum had been collected at presentation (n = 387 of 446). At baseline, subjects completed a sociodemographic schedule, and symptom severity was assessed using the Positive and Negative Syndrome Scale (PANSS) (14) and the Calgary symptom severity was assessed using the Positive and Negative Syndrome Scale (PANSS) (14) and the Calgary Depression Scale for Schizophrenia (CDSS) (15). Patients were then treated with amisulpride following a standardized protocol for 4 weeks (13). The duration of untreated psychosis was estimated at baseline, using information from the patient, relatives and caregivers, and clinical records. It was defined as the time (in months) between the onset of frank psychotic symptoms to the baseline assessment. At 4 weeks, clinical response to amisulpride was assessed using the PANSS, CDSS, and the Clinical Global Impressions (CGI) Scale (16). Adverse effects of treatment were assessed using the Udvalg for Kliniske Undersogelser side effect rating scale (17). Remission was defined according to the criteria by Andreasen et al. (18), according to which 8 specific symptoms (PANSS items P1, P2, P3, N1, N4, N6, G5, and G9) of schizophrenia as measured by the PANSS (14) are at most only mildly present (maximum rating of 3) so that they do not interfere with daily life functioning. However, because the assessment was conducted after 4 weeks, the conventional requirement for meeting the above remission criteria for 6 months (18) was not used. All clinical ratings were completed, entered in the database, and locked before antibody testing; therefore, analyses were retrospective, and antibody status was not known at enrollment.

Immunosassays

Serum samples were tested for NMDAR IgG antibodies using a live cell–based assay as described above (4). A live cell–based assay was used because we found that this had greater sensitivity than a fixed cell–based assay, detecting sevenfold more positive samples, which all nonetheless showed on single nanoparticle imaging a signature strongly indicative of binding to the NMDAR (4).

Statistical Analysis

Statistical analyses were performed using SPSS (version 23; IBM Corp., Armonk, NY). Demographic variables were compared between seropositive and seronegative patients using independent samples t tests and Mann-Whitney U tests for continuous variables and χ2 and Fisher’s exact tests for categorical data. For clinical scales (PANSS, CDSS, and CGI), multiple linear regressions were carried out within the general linear model with NMDAR antibody status (positive or negative), sex, and race as factors and with age as covariate. Significance threshold was set to p < .05; mean ± SD are presented unless otherwise stated. Owing to the exploratory nature of the analyses, significance values are given for two-tailed tests where applicable and uncorrected for multiple comparisons.

RESULTS

Participants and Prevalence of NMDAR Antibodies

A total of 387 subjects had a baseline assessment and blood sample analyzed. Fifteen of 387 (3.9%) subjects had NMDAR IgG antibodies detectable in serum, and 372 were seronegative. These subjects were included in the analyses of demographic data, duration of untreated psychosis, and baseline symptoms. Demographic and baseline clinical data are presented in Table 1.

In total, 92 subjects were excluded from the follow-up analysis. Two subjects dropped out of the study before receiving amisulpride (one because of returning to their home country to be with family, another because of moving to a different region of the same country); both were NMDAR antibody seronegative. A further 90 subjects received amisulpride but were excluded (either dropped out/excluded before finishing 4 weeks of treatment or excluded from analyses after completion of treatment) because of the following reasons: adverse events (n = 8), protocol violation (n = 42), subject did not wish to continue (n = 27), subject died (n = 1), at the discretion of the investigator (n = 4; includes violence [n = 1], prolonged hospitalization [n = 1], clinical inefficacy [n = 1], retrospectively felt not to meet criteria [n = 1]) and other
reasons \( (n = 8) \). Of these 90 excluded subjects, 4 were seropositive for NMDAR antibodies. Reasons for exclusion of these 4 patients were protocol violation \( (n = 1) \), death (died by suicide) \( (n = 1) \), withdrew because of weight gain and fatigue \( (n = 1) \), and other (lost to follow-up: \( n = 1) \).

Table S1 summarizes demographic and clinical differences between subjects who were included and excluded (dropped out or excluded after treatment as described above) for follow-up. The frequency of NMDAR antibodies was 3.7% in the subjects who were included in the follow-up study and 4.3% in subjects excluded from the follow-up study \( (p = .761) \).

Excluded subjects were less frequently white than included subjects. The duration of psychosis was shorter for excluded \( (\text{median, 3 months}) \) than for included \( (\text{median, 4 months}) \) subjects \( (p = .041) \). In total, 295 (11 seropositive and 284 seronegative) subjects completed 4 weeks of amisulpride treatment; these subjects were included in analyses of treatment response.

The remaining seropositive subjects did not differ from those who were seronegative with respect to age, gender, body mass index, smoking status, or recreational drug use (Table 1). However, the duration of untreated psychosis was significantly shorter in the seropositive subjects: the median duration was 1.5 months (interquartile range, 1–3.5), compared with 4.0 months (interquartile range, 2–8) in the seronegative subjects \( (p = .031) \) (Figure 1B).

Clinical Associations of NMDAR Antibody Seropositivity

At baseline, subjects who were NMDAR antibody seropositive did not differ from seronegative subjects on any measure of symptom severity (Table 2 and Figure 1).

Response to Antipsychotic Treatment

The mean reduction in PANSS total score over the treatment period was not greater in subjects who were seropositive than in those who were seronegative \( (p = .098) \) (Figure 1C), nor was the CGI score at 4 weeks different between groups \( (p = .075) \). CGI improvement scores at 4 weeks indicated a greater degree of observed clinical improvement relative to baseline in seropositive patients \( (2.64 \pm 0.67) \) than in seronegative patients \( (3.34 \pm 1.04; p = .044) \) (Table 3).
Psychiatry
Biological

psychosis duration was retrospective, it was dif-erently measured. However, this would require a large number of samples, to assessment of subjects in the clinical high risk. This issue could be addressed by conducting a prospective serostatus-associated differences in variables that have been reported: seropositive subjects had a signifi-cantly shorter duration of untreated psychosis before the baseline assessment than seronegative patients and 9 (81.8%) seropositive patients (p = .394). There was no difference between seronegative and seropositive subjects in the frequency of adverse effects after 4 weeks of treatment (Table 4).

DISCUSSION
Our first hypothesis was that seropositive patients with FEP would have a relatively short duration of untreated psychosis on the basis that the presentation of NMDAR antibody encephalitis is typically subacute. This hypothesis was supported: seropositive subjects had a significantly shorter duration of psychosis before the baseline assessment than seronegative subjects. This difference was not attributable to serostatus-associated differences in variables that have been (inconsistently) associated with a shorter duration of untreated psychosis, such as male sex, younger age at diagnosis, or substance use (19,20). Because the assessment of untreated psychosis duration was retrospective, it was difficult to precisely measure when frank psychotic symptoms first emerged. This issue could be addressed by conducting a prospective study, with ascertainment of subjects in the clinical high risk phase. However, this would require a large number of samples, as the prevalence of NMDAR antibodies in this population is similarly low [approximately 5% (21)], and only a minority of subjects with clinical high risk will later develop psychosis (22).

Our second hypothesis, partly based on data from patients with psychosis in the context of NMDAR antibody encephalitis, was that seropositive patients with FEP would show a relatively poor symptomatic response to antipsychotic medication. However, seropositive patients showed a similar improvement in symptoms to seronegative patients after 4 weeks of treatment with amisulpride, with 82% of seropositive patients achieving remission within this short time frame. This relatively good response was evident both in the investigator-rated change in the PANSS total score and in the evaluations made using the CGI, in which the mean scores of seropositive patients indicated that they were much improved, whereas mean scores of seronegative patients indicated minimal improvement in this group. Both sets of ratings were made before determining patient antibody status. Whereas the CGI improvement scale suggests a more positive response to antipsychotics in seropositive patient, the more detailed and objective PANSS failed to show such between-group differences (although the size of the seropositive group may not have been large enough to clearly demonstrate that seropositive patients do not respond better to amisulpride than sero-negative patients).

We also predicted that seropositive patients would be more likely to experience adverse effects of antipsychotic

| Measure | NMDAR Ab Negative, n = 373 | NMDAR Ab Positive, n = 15 | B | p Value, NMDAR Ab Negative vs. Positive |
|---------|-----------------------------|--------------------------|---|--------------------------------------|
| PANSS Total, Baseline | 78.78 ± 19.00 | 75.80 ± 19.10 | 3.27 | .513 |
| PANSS Positive | 20.12 ± 5.55 | 20.13 ± 6.38 | 0.096 | .949 |
| PANSS Negative | 19.89 ± 7.10 | 17.80 ± 6.95 | 1.92 | .302 |
| PANSS General | 36.76 ± 9.99 | 37.87 ± 9.86 | 1.26 | .631 |
| CDSS | 13.31 ± 4.48 | 13.07 ± 4.37 | 0.362 | .759 |
| CGI | 5.53 ± 0.92 | 5.33 ± 1.19 | −0.001 | .998 |

Continuous variables are presented as mean ± SD.

Ab, antibody; CDSS, Calgary Depression Scale for Schizophrenia; CGI, Clinical Global Impressions; NMDAR, NMDA receptor; PANSS, Positive and Negative Syndrome Scale.

Regression coefficient from multiple regression procedure.

| Measure | NMDAR Ab Negative, n = 11 | NMDAR Ab Positive, n = 15 | B | p Value, NMDAR Ab Negative vs. Positive |
|---------|-----------------------------|--------------------------|---|--------------------------------------|
| PANSS Total, Baseline | 74.21 ± 18.77 | 5.04 | .341 |
| PANSS Positive | 50.45 ± 20.46 | 8.22 | .145 |
| PANSS Negative | −38.01 ± 38.97 | −59.56 ± 26.91 | 19.55 | .098 |
| Percentage Change in Total PANSS Scores | −38.01 ± 38.97 | −59.56 ± 26.91 | 19.55 | .098 |
| Percentage Change in CDSS Scores | −7.25 ± 24.81 | −10.54 ± 12.31 | 2.64 | .741 |
| CGI, Posttreatment | 3.82 ± 1.25 | 0.604 | .075 |
| CGI Improvement | 2.64 ± 0.67 | 4.27 | .044 |
| Number in Remission | 196 (69.3%) | 9 (81.8%) | 0.683 | .394 |

Values are presented as mean ± SD or n (%).

Ab, antibody; CDSS, Calgary Depression Scale for Schizophrenia; CGI, Clinical Global Impressions; NMDAR, NMDA receptor; PANSS, Positive and Negative Syndrome Scale.

Regression coefficient from multiple or logistic regression procedure.
NMDAR Antibodies and Antipsychotic Response

Table 4. Frequency of Subjects Experiencing Adverse Events

| Type of Adverse Event | NMDAR Ab Negative, n = 284 | NMDAR Ab Positive, n = 11 | p Value, NMDAR Ab Negative vs. Positive |
|-----------------------|-----------------------------|---------------------------|----------------------------------------|
| Psychic               | 144 (50.7%)                 | 7 (63.6%)                 | .542                                   |
| Neurological          | 55 (19.4%)                  | 3 (27.3%)                 | .457                                   |
| Autonomic             | 69 (23.3%)                  | 4 (36.4%)                 | .474                                   |
| Other                 | 119 (41.9%)                 | 8 (72.7%)                 | .061                                   |
| None                  | 60 (21.1%)                  | 2 (18.2%)                 | 1.000                                  |

Values are presented as n (%).

Ab, antibody; NMDAR, NMDA receptor.

medication than seronegative patients. While there was no difference in the frequency of adverse effects between the groups, this lack of difference should perhaps be interpreted with caution because of the relatively low number of seropositive patients and low frequency of adverse events. The absence of the predicted increased frequency of adverse effects in the seropositive patients was not attributable to receiving antipsychotic drugs that are rarely associated with adverse effects or that were prescribed at low doses, as both groups were treated with the same medication in similar doses. Moreover, compared with other antipsychotics, amisulpride is relatively frequently associated with extrapyramidal side effects, which are the type that have been associated with antipsychotic treatment in NMDAR antibody encephalitis (6,7).

One patient who was seropositive for NMDAR antibodies committed suicide 7 days after discontinuing amisulpride; this was the only suicide reported. Suicidality and completed suicide have been reported in NMDAR antibody encephalitis (23) but to our knowledge have not been reported as a feature of patients without encephalitis who are seropositive for NMDAR antibodies. Post hoc analyses (not reported here) showed no difference between seropositive and seronegative FEP on the suicidality subscale of the CDSS. This finding and the observed overall lack of association between serostatus and symptom severity across domains suggest that the seropositive status in this patient was coincidental.

Our results suggest that serum NMDAR antibodies may have limited disease relevance in FEP, insofar as they were associated with a shorter duration of untreated psychosis but not with a differential response to antipsychotic treatment. Contrary to our hypothesis, the data suggest that NMDAR antibodies may be associated with a good response to antipsychotic treatment. We consider the most likely reason for this finding to be that NMDAR antibodies were not causative of these patients’ psychosis and indeed that they may be unrelated to their illness altogether. However, since we included no explicit measurement of central nervous system (CNS) inflammation, except by magnetic resonance imaging, which is known not to be sensitive to autoimmune encephalopathies, the possibility of some causal pathogenic role cannot be ruled out. In such an instance, which we consider unlikely, it is possible that improvements in symptoms may have been driven by factors other than antipsychotic medication in the seropositive group. In some patients with FEP, and particularly in those with a brief duration of psychosis, symptoms can remit in the absence of antipsychotic medication (24). It is also possible that psychosis associated with NMDAR antibodies is more likely to spontaneously remit (independent of treatment) than a psychotic disorder that is not associated with antiautoantibodies [possibly akin to other transient autoimmune phenomena such as self-limiting arthritis with evidence of autoimmune involvement (25)]. The clinical course of FEP is heterogeneous, with some patients experiencing only one episode and others exhibiting a multiepisode course or a relapsing-remitting course with accumulation of disability and comorbidity. Future work is planned to establish whether patients with FEP who are NMDAR antibody seropositive demonstrate a particular illness trajectory.

It will also be of interest to explore the longitudinal course of NMDAR antibody serostatus in patients who were seropositive (and indeed seronegative) at baseline, with a view to assessing if serostatus changes in association with symptomatic response to treatment, functional status, or relapse. There is recent evidence from humans and animals that serostatus fluctuates over time and that NMDAR antibody production may occur as a response to chronic stress (although this effect was more marked with non-IgG isotypes) (26). Furthermore, the presence of functional unmutated IgG antibodies (27) suggests the possibility that these antibodies may constitute part of the natural antibody repertoire, potentially serving an adaptive physiological function. One hypothesis might be that NMDAR antibodies in patients with psychosis are a secondary immune response to whichever nonautoimmune NMDAR dysfunction is the primary driver of the illness.

To the best of our knowledge, this is the largest study of NMDAR antibodies in FEP. However, the prevalence and, therefore, sample size of patients who are seropositive are low. Our study excluded patients with organic psychoses and required patients to be well enough to consent to and complete a clinical trial. This suggests the possibility that our sample may be biased toward patients who are more likely to show a good response to antipsychotic medication than the general clinical population. A recent study including acutely unwell patients with FEP, of whom many were incapacitous (i.e., lacked capacity to consent at the time of enrollment and blood sampling), found a somewhat higher rate of NMDAR antibody seropositivity, along with considerable evidence that the antibodies were clinically relevant in these patients (concurrent CNS NMDAR antibodies, inflammation, and good response to immunotherapy) (10).

Owing to limited serum availability, only IgG NMDAR antibodies were measured. Although IgA and IgM antibodies are
not always thought to be pathogenic and indeed are not considered to be causal in NMDAR antibody encephalitis, it is conceivable that they could still have a useful role as biomarkers of antipsychotic response. Another limitation was that cerebrospinal fluid was not available for analysis, which can provide evidence of CNS inflammation by means of white blood cell count, protein count, and the presence of oligoclonal bands. A goal for future studies is to combine the measurement of serum antibodies with the collection of cerebrospinal fluid so that the prevalence of CNS inflammation in seropositive patients and its impact on clinical outcomes can be examined.

Conclusions

This study suggests that in a patient with psychosis, a positive serum NMDAR antibody result does not indicate that treatment with antipsychotic medication will be ineffective or associated with increased adverse effects. This supports recent guidelines for the investigation and management of suspected autoimmune psychosis (28) that propose that patients who are psychotic and are identified as NMDAR antibody seropositive should undergo further electroencephalogram, magnetic resonance imaging, and cerebrospinal fluid analysis to clarify the clinical significance of the positive antibody result. Only in the presence of abnormalities confirmed in these modalities is it considered likely that NMDAR antibody seropositivity is truly indicative of active CNS inflammation and that immunotherapy might be indicated (28).

ACKNOWLEDGMENTS AND DISCLOSURES

This study was supported by a clinical research fellowship grant from the Welcome Trust (Grant No. 105758/214/2 [to TAP]) and a public grant, BETPSY project, overseen by the French National Research Agency, as part of the second “Investissements d’Avenir” program (Grant No. ANR-18-RHUS-0012 [to JH]).

TAP, PM, and ML conceived the study. TAP performed analyses and wrote the manuscript. CI, EC, LJ, LG, VR, JH, and JJ performed analyses and wrote the manuscript. AV, RSK, AD, JS, and AE assisted with data interpretation and edited the manuscript. ML, PD, and PM oversaw data collection, assisted with study design and data interpretation, and edited the manuscript. The authors report no biomedical financial interests or potential conflicts of interest.

ClinicalTrials.gov: OPTiMiSE (Optimization of Treatment and Management of Schizophrenia in Europe); EudraCT-Number: 2010-020185-19; NCT01248195.

ARTICLE INFORMATION

From the Department of Psychiatry Studies (TAP, CI, AE, PM), Division of Neuroscience (EC), Department of Neuroimaging (JS), Centre for Neuroimaging Sciences, Centre for Developmental Neurobiology (UJ), and Department of Psychological Medicine (PD), Institute of Psychiatry, Psychology and Neuroscience, King’s Health Partners, King’s College London; South London and Maudsley NHS Foundation Trust (TAP, JS, PM); Institute of Mental Health (AD), University College London; London; Nuffield Department of Clinical Neurosciences (AV, LJ), John Radcliffe Hospital, Oxford, United Kingdom; Department of Psychiatry, Psychotherapy, and Psychosomatics (DR), Martin-Luther-University Halle-Wittenberg, Halle, Germany; Rare Disease Reference Center on Autoimmune Encephalitis (VR, JH), Hospices Civils de Lyon, Institut NeuroMypoGene Institut National de la Santé et de la Recherche Médicale U1217/Centre National de la Recherche Scientifique, University Claude Bernard, Universite de Lyon, Lyon; Psychiatry and Addictology Department (DMU IMPACT) (SJ, ML), University Paris Est Créteil, Hopitaux Universitaires Henri Mondor, L’Assistance Publique-Hôpitaux de Paris; Translational Neuropsychiatry Laboratory (ML), Institut National de la Santé et de la Recherche Médicale U955; FondaMental Foundation (ML), Créteil; Interdisciplinary Institute for Neuroscience (JJ, LG), University of Bordeaux, Bordeaux, France; and Department of Psychiatry (RSK), Icahn School of Medicine at Mount Sinai, New York, New York.

Address correspondence to Thomas A. Pollak, Ph.D., at thomas.pollak@kcl.ac.uk.

Received Aug 17, 2020; revised Nov 3, 2020; accepted Nov 16, 2020. Supplementary material cited in this article is available online at https://dx.doi.org/10.1016/j.biopsych.2020.11.014.

REFERENCES

1. Pearlman DM, Najjar S (2014): Meta-analysis of the association between N-methyl-d-aspartate receptor antibodies and schizophrenia, schizoaffective disorder, bipolar disorder, and major depressive disorder. Schizophr Res 157:249–258.
2. Pollak TA, McCormack R, Peakman M, Nicholson TR, David AS (2014): Prevalence of anti-N-methyl-D-aspartate (NMDA) receptor [corrected] antibodies in patients with schizophrenia and related psychoses: A systematic review and meta-analysis. Psychiatr Med 44:2475–2487.
3. Jézéquel J, Johansson EM, Dupuis JP, Rogemond V, Gréa H, Keilermayer B, et al. (2017): Dynamic disorganization of synaptic NMDA receptors triggered by autoantibodies from psychotic patients. Nat Commun 8:1791.
4. Jézéquel J, Rogemond V, Pollak T, Lepieux M, Jacobson L, Gréa H, et al. (2017): Cell- and single molecule-based methods to detect anti-N-methyl-D-aspartate receptor autoantibodies in patients with first-episode psychosis from the OPTiMiSE project. Biol Psychiatry 82:766–772.
5. Dahn L, Ott C, Steiner J, Stepaniak B, Teegen B, Saschenbrecker S, et al. (2014): Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol 76:82–94.
6. Lejuste F, Thomas L, Picard G, Desestret V, Ducray F, Rogemond V, et al. (2016): Neuroleptic intolerance in patients with anti-NMDAR encephalitis. Neurol Neuroimmunol Neuroinflamm 3:e2680.
7. Punja M, Pomerleau AC, Devlin JJ, Morgan BW, Schier JG, Schwartz MD (2013): Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis: An etiology worth considering in the differential diagnosis of delirium. Clin Toxicol (Phila) 51:794–797.
8. Graus F, Titaulea MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. (2016): A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15:391–404.
9. Zandi MS, Deakin JB, Morris K, Buckley C, Jacobson L, Scoriels L, et al. (2014): Immunotherapy for patients with acute psychosis and serum N-methyl-D-aspartate receptor (NMDAR) antibodies: A description of a treated case series. Schizophr Res 160:193–195.
10. Scott JG, Gillis D, Ryan AE, Hargovan H, Gundarpi N, McKeon G, et al. (2018): The prevalence and treatment outcomes of antineuronal antibody-positive patients admitted with first episode of psychosis. Bipolar Open 4:89–74.
11. Kayser MS, Dalmau J (2016): Anti-NMDA receptor encephalitis, autoimmunity, and psychosis. Schizophr Res 176:36–40.
12. Ehrenreich H (2017): Autoantibodies against the N-methyl-d-aspartate receptor subunit NR1: Untangling apparent inconsistencies for clinical practice. Front Immunol 8:181.
13. Kahn RS, Winter van Rossum I, Leucht S, McGuire P, Lewis SW, Leboyer M, et al. (2018): Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizoaffective disorder (OPTiMiSE): A three-phase switching study. Lancet Psychiatry 5:797–807.
14. Kay SR, Fiszbein A, Opler LA (1987): The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276.
15. Addington D, Addington J, Schissel B (1990): A depression rating scale for schizophrenics. Schizophr Res 3:247–251.
16. Guy W (1976): ECDEU Assessment Manual for Psychopharmacology. Rockwell: United States Department of Health, Education, and Welfare.
17. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987): The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1–100.

18. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR (2000): Remission in schizophrenia: Proposed criteria and rationale for consensus. Am J Psychiatry 157:441–449.

19. Souaiby L, Gauthier C, Kazes M, Mam-Lam-Fook C, Daban C, Plaze M, et al. (2019): Individual factors influencing the duration of untreated psychosis. Early Interv Psychiatry 13:798–804.

20. Broussard B, Kelley ME, Wan CR, Cristofaro SL, Crisafio A, Haggard PJ, et al. (2013): Demographic, socio-environmental, and substance-related predictors of duration of untreated psychosis (DUP). Schizophr Res 148:93–98.

21. Pollak TA, Kempton MJ, Iyegbe C, Vincent A, Irani SR, Coutinho E, et al. (2020): Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis [published online ahead of print Oct 19]. Mol Psychiatry.

22. Fusar-Poli P, Cappucciati M, Borgwardt S, Woods SW, Addington J, Nelson B, et al. (2016): Heterogeneity of psychosis risk within individuals at clinical high risk: A meta-analytical stratification. JAMA Psychiatry 73:113–120.

23. Zhang L, Sander JW, Zhang L, Jiang XY, Wang W, Shuang K, et al. (2017): Suicidality is a common and serious feature of anti-N-methyl-D-aspartate receptor encephalitis. J Neurol 264:2378–2386.

24. Fusar-Poli P, Cappucciati M, Bonoldi I, Hui LM, Rutigliano G, Stahl DR, et al. (2016): Prognosis of brief psychotic episodes: A meta-analysis. JAMA Psychiatry 73:211–220.

25. Norli ES, Brinkmann GH, Kvien TK, Bjerneboe O, Haugen AJ, Nygaard H, et al. (2016): Self-limiting arthritis among patients fulfilling the 2010 ACR/EULAR classification criteria for rheumatoid arthritis in a very early arthritis cohort. Semin Arthritis Rheum 46:272–278.

26. Pan H, Steixner-Kumar AA, Seelbach A, Deutsch N, Ronnenberg A, Tapken D, et al. (2020): Multiple inducers and novel roles of autoantibodies against the obligatory NMDAR subunit NR1: A translational study from chronic life stress to brain injury [published online ahead of print Feb 24]. Mol Psychiatry.

27. Wenke NK, Kreye J, Andrejak E, van Casteren A, Leubner J, Murguetio MS, et al. (2019): N-methyl-D-aspartate receptor dysfunction by unmutated human antibodies against the NR1 subunit. Ann Neurol 85:771–776.

28. Pollak TA, Lennox BR, Müller S, Benros ME, Prüss H, Tebartz van Elst L, et al. (2020): Autoimmune psychosis: An international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry 7:93–108.